Surface Oncology to Present Clinical Updates for SRF388 and SRF617
SRF388 Phase 1 Update to be Presented at American Society for Clinical Oncology Annual Meeting
Company to Hold Webcast to Review Data from Ongoing SRF388 and SRF617 Phase 1 Clinical Studies on Friday, June 4th at 8:00 a.m. ET
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a scientific poster sharing clinical data from its Phase 1 study of SRF388 will be presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting, to be held virtually June 4-8, 2021. In conjunction, Surface will host a webcast on Friday, June 4, 2021 at 8:00 a.m. to review the SRF388 clinical data as well as to provide a clinical update from the company’s ongoing SRF617 Phase 1 study.
“We’re excited to share clinical data on our lead therapeutic candidates, both of which are first-in-class,” said Alison O’Neill, M.D., chief medical officer at Surface Oncology. “Findings from the ongoing Phase 1 clinical trials of SRF617 and SRF388 support our scientific hypotheses and may provide an important step forward in the treatment of patients with cancer who have not benefitted from other immuno-oncology approaches.”
Presentation Type: e-poster (Abstract: 2551)
The e-poster website will be launched on Friday, June 4, 2021, and will remain available for viewing through Tuesday, July 6, 2021. The full poster will be placed on Surface Oncology’s website following the presentation.
About the SRF388-101 Clinical Trial:
About the SRF617-101 Clinical Trial:
About Surface Oncology:
Cautionary Note Regarding Forward-Looking Statements:
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Surface Oncology’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to Surface Oncology’s ability to successfully develop SRF388, SRF617 and its other product candidates through current and future milestones or regulatory filings on the anticipated timeline, if at all, the therapeutic potential of Surface Oncology’s product candidates, the risk that results from preclinical studies or early clinical trials may not be representative of larger clinical trials, the risk that Surface Oncology’s product candidates, including SRF388 and SRF617, will not be successfully developed or commercialized, the risks related to Surface Oncology’s dependence on third-parties in connection with its manufacturing, clinical trials and preclinical studies, and the potential impact of COVID-19 on our clinical and preclinical development timelines and results of operations. Additional risks and uncertainties that could affect Surface Oncology’s future results are included in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ending December 31, 2020, which is available on the Securities and Exchange Commission’s website at www.sec.gov and Surface Oncology’s website at www.surfaceoncology.com.
Additional information on potential risks will be made available in other filings that Surface Oncology makes from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements contained in this press release are based on assumptions that Surface Oncology believes to be reasonable as of this date. Except as required by law, Surface Oncology assumes no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.
The New World of Remote Work
JSON Within A Relational Database